206 care center directors sign a letter citing clinical consequences if decision moves forward.
Site Search
The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.
If you receive financial assistance from Vertex GPS™ for a modulator therapy (e.g., Trikafta®, Symdeko®, Orkambi®, or Kalydeco®), you may be impacted by changes Vertex has made to its copay assistance program. The following tips can help you understand how you may be impacted and what next steps may be available to you.
Las personas con fibrosis quística y sus familias se han enfrentado a importantes cargas económicas debido a los programas acumuladores de copago. Familiarícese con estos programas y lo que implican para usted y sus seres queridos.
Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.
People with cystic fibrosis and their families have faced significant cost burdens due to copay accumulator programs. Get caught up on these programs and what they mean for you and your loved ones.
Vertex’s copay assistance changes add an undue burden for people living with an already expensive, challenging lifelong disease.
On behalf of the CF community, the Cystic Fibrosis Foundation has expressed its concern to the Social Security Administration (SSA) about a proposed rule that could make it more difficult for people with CF to receive disability benefits.
In an effort led by Congressional Cystic Fibrosis Caucus co-chairs Representatives Edward Markey (D-MA) and Tom Marino (R-PA) and Senator Michael Bennet (D-CO), 37 key members of Congress sent letters to the Social Security Administration (SSA) expressing their concern about a proposed rule that could make it more difficult for people with CF to receive disability benefits.
Lack of insurance coverage for cystic fibrosis-related medications remains a top concern for people with CF and their families, a recent study found.